Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04846829 · ClinicalTrials.gov registry record · Early Phase 1
Effects of Intravenous (IV) Citalopram Hydrochloride During Transcranial Magnetic Stimulation in Major Depressive Disorder (MDD)
A Early Phase 1 study of Major Depressive Disorder, sponsored by University of California, Los Angeles.
- Active
- Registry status
- Early Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT04846829: Active Early Phase 1 study of Major Depressive Disorder, sponsored by University of California, Los Angeles.
NCT04846829 is a Early Phase 1 study of Major Depressive Disorder that is active but no longer recruiting, run by University of California, Los Angeles. The registered enrollment target is 30 participants, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04846829, a Early Phase 1 study of Major Depressive Disorder, is active but no longer recruiting, sponsored by University of California, Los Angeles.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will recruit 30 subjects diagnosed with Major Depressive Disorder (MDD). Subjects will be recieve one infusion treatment of citalopram or placebo and 10 treatments of a form of transcranial magnetic stimulation, theta burst stimulation (TBS). Subjects will also undergo brain scans, quantitative electroencephalography (qEEG) brain activity recordings, and mood surveys. Study activities will be performed over the course of 4 weeks.
Primary Outcome
A 17-item, clinician-administered depression assessment scale pertaining to symptoms of depression experienced over the past week. Each item is scored between 0-4 points. Scoring is based on the 17-item scale and scores of 0-7 are considered as being normal, 8-16 suggest mild depression, 17-23 moderate depression and scores over 24 are indicative of severe depression; the maximum score being 52 on the 17-point scale.
Conditions Studied
Interventions
- DRUG Placebo
- DEVICE intermittent theta burst stimulation
- DRUG intravenous citalopram hydrochloride (CIT)
- DEVICE continuous theta burst stimulation
Study Locations (1)
California
- UCLA Depression Research and Clinic Program - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2017-04-24 |
| Est. Completion | 2028-04-24 |
| Phase | Early Phase 1 |
What the registry record for NCT04846829 still lists
NCT04846829 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT04846829 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04846829 about?
NCT04846829 is a clinical study titled "Effects of Intravenous (IV) Citalopram Hydrochloride During Transcranial Magnetic Stimulation in Major Depressive Disorder (MDD)". This study will recruit 30 subjects diagnosed with Major Depressive Disorder (MDD). Subjects will be recieve one infusion treatment of citalopram or placebo and 10 treatments of a form of transcranial magnetic stimulation, theta burst stimulation (TBS). Subjects will also undergo brain scans, quanti...
What is the current status of trial NCT04846829?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2017-04-24. Estimated completion is 2028-04-24.
What conditions does trial NCT04846829 study?
This clinical trial studies the following conditions: Major Depressive Disorder.
What interventions are being tested in trial NCT04846829?
The interventions under investigation include: Placebo (DRUG), intermittent theta burst stimulation (DEVICE), intravenous citalopram hydrochloride (CIT) (DRUG), continuous theta burst stimulation (DEVICE).
Who is sponsoring clinical trial NCT04846829?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04846829 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04846829's enrollment target sits among peer trials
30 220th of 282 higher than 56 of 282 other Major Depressive Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Major Depressive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Xenon Inhalation Therapy for Major Depressive Disorder and Bipolar Disorder
RECRUITING · Early Phase 1
-
Mood Effects of Serotonin Agonists: Depression
RECRUITING · Early Phase 1
-
Glutamatergic Adaptation to Stress as a Mechanism for Anhedonia and Treatment Response With Ketamine
RECRUITING · Early Phase 1
-
Ketamine Associated ACC GABA and Glutamate Change and Depression Remission:
ACTIVE NOT RECRUITING · Early Phase 1
-
Testing a Transdiagnostic TMS Treatment Target
ACTIVE NOT RECRUITING · Early Phase 1
-
Feasibility Pilot of Accelerated Stimulation With TMS for Treatment of Major Depressive Disorder (FAST-MDD)
COMPLETED · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI